Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Immune Design combo sees positive data in mouse models
December 2015
SHARING OPTIONS:

SEATTLE—Immune Design recently announced new preclinical data demonstrating that a dendritic-cell targeting lentiviral vector from its ZVex immunotherapy platform administered with G100, which contains a potent synthetic TLR4 agonist, synergizes with immune checkpoint inhibitors and demonstrates potent local and systemic antitumor activity in cancer models. The ZVex delivery system harnesses a reengineered virus to carry genetic information of a tumor antigen selectively to dendritic cells in the skin, which results in the generation of cytotoxic T cells. These data come from a murine B16 melanoma model, which showed that intratumoral injections of G100 improves the trafficking of ZVex-induced antigen-specific CD8 T cells into tumors and induces systemic antitumor immunity mediated by antigen spreading. This work also showed that combining G100 or a ZVex agent with both anti-PD1 and anti-PDL1 antibodies led to increased efficacy.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.